Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Upgraded by Baird R W

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by research analysts at Baird R W to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Several other research firms have also weighed in on CPRX. Bank of America reaffirmed a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. HC Wainwright boosted their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Finally, Robert W. Baird began coverage on Catalyst Pharmaceuticals in a research report on Tuesday. They set an “outperform” rating and a $28.00 price target on the stock. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $32.25.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $23.09 on Monday. The business’s 50 day simple moving average is $22.03 and its 200 day simple moving average is $20.83. Catalyst Pharmaceuticals has a 52-week low of $13.12 and a 52-week high of $24.64. The firm has a market cap of $2.75 billion, a PE ratio of 19.57, a P/E/G ratio of 2.25 and a beta of 0.80.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by company insiders.

Institutional Trading of Catalyst Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $50,000. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $65,000. Finally, KBC Group NV lifted its position in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 1,542 shares during the period. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.